- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 04.08. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches First-of-Its-Kind ZEO Xperience, a Three-Day Immersive Regenerative Medicine Experience for Healthcare Professionals | 213 | ACCESS Newswire | Hosted at Fort Lauderdale's newly reimagined Pier Sixty-Six Resort, the inaugural event combines cutting-edge biologics education, hands-on clinical training, practice growth strategies, and latest... ► Artikel lesen | |
| 24.07. | Zeo ScientifiX, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation | 292 | ACCESS Newswire | Operating from Nova Southeastern University's Center for Collaborative Research, ZEO ScientifiX is expanding physician education, scientific collaboration, and regenerative biologic innovation as Florida... ► Artikel lesen | |
| 08.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026 | 334 | ACCESS Newswire | Company reports revenue growth of 124.6% for the quarter ended April 30, 2026 and 79.9% for the six months ended April 30, 2026, as compared to the same periods one year earlier as commercial momentum... ► Artikel lesen | |
| 01.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution | 384 | ACCESS Newswire | "One Year Later, Three States Stronger" program will examine lessons learned from Florida's first year into their pioneering stem cell law and provide physicians from other states an insight of what... ► Artikel lesen | |
| 16.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Donates Products to Support Pediatric Burn Reconstruction Mission in Peru | 228 | ACCESS Newswire | ZEO Medical Advisory Board Member Dr. Constantino Mendieta joins humanitarian effort providing reconstructive care to children recovering from severe burn injuries in Cusco, Peru DAVIE, FL / ACCESS... ► Artikel lesen | |
| 15.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine | 492 | ACCESS Newswire | Company strengthens scientific leadership as regenerative medicine gains national momentum DAVIE, FL / ACCESS Newswire / June 9, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company")... ► Artikel lesen | |
| 27.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast | 631 | ACCESS Newswire | After training more than 600 physicians in under a year, the biologics research and products company now turns its focus to assisting physicians in educating their patients on the science of regenerative... ► Artikel lesen | |
| 12.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone. | 221 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / May 12, 2026 / ZEO ScientifiX (OTCQB:ZEOX) ("ZEO" or the "Company"), a regenerative medicine products company serving physician-run clinics across the United... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians | 220 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 21, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX"), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Kurssprünge und Kaufempfehlungen! Neues Kursziel bei Almonty! CTS Eventim und BioNTech melden sich zurück! | Was für ein Comeback! Im August ist die Aktie von Almonty um über 50 % explodiert! Dafür gibt es gute Gründe. Wolfram ist im Westen knapp und wird von der hochfahrenden Waffenproduktion in den USA dringend... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | QIAGEN ernennt Jonathan M. Pratt zum Vorstandschef | Bad Marienberg (www.anleihencheck.de) - QIAGEN N.V. ((ISIN NL0015001WM6/ WKN A41HBE; NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Milliardenmarkt Krebs: Moderna und Merck läuten die nächste Biotech-Ära ein | Ein Durchbruch in der Krebsforschung sorgt für Euphorie an der Börse. Moderna und Merck feiern einen Studienerfolg. Jetzt hoffen Anleger auf die nächste große Biotech-Rallye und neue Milliardenmärkte.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen ZEO SCIENTIFIX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.